CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder

Chihiro Namatame, Tatsuro Misu, Yoshiki Takai, Shuhei Nishiyama, Ichiro Nakashima, Kazuo Fujihara, Masashi Aoki

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder'. Together they form a unique fingerprint.

Medicine & Life Sciences